Quantcast

Latest Humanized antibody Stories

2008-10-02 09:00:07

DALLAS, Oct. 2 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (BULLETIN BOARD: ACCP) presented data this week from preclinical studies on Angiolix showing that by blocking lactadherin, Angiolix has both an anti-angiogenic effect as well as a direct anti-proliferative effect on tumors themselves. In preclinical models of human breast cancer (MX-1), Angiolix had a significant anti-cancer effect in vivo; this effect was enhanced when Angiolix was given in combination with...

2008-09-26 09:00:40

4-Antibody AG today announced that Dr. Richard Mason has joined the company as Chief Executive Officer and Geschaeftsfuehrer. Dr. Mason joins 4-Antibody from venture capital firm Advent Venture Partners, an investor in 4-Antibody, where he has been an Executive-in-Residence. Previously Dr. Mason was Senior Vice President Business Development at Cambridge Antibody Technology plc (CAT). As head of CAT's business development team he was responsible for numerous transactions with major...

2008-08-07 18:01:54

BERKELEY, Calif., Aug. 7, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its results for the quarter ended June 30, 2008. "In the second quarter of 2008, XOMA made clear progress in its proprietary clinical programs, presented related data at two major medical conferences, increased its cash balance, and grew its royalty revenues," said Steven Engle, Chairman and Chief Executive Officer of XOMA. "The...

2008-08-05 09:01:31

CAMBRIDGE, Mass., Aug. 5 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases, announced today that Genentech, a collaborator, has moved a modified version of TRX1, MTRX1011A, an anti-CD4 monoclonal antibody, into a phase 1 clinical trial that has begun enrolling patients. The clinical trial is evaluating the safety and tolerability of both single and multiple doses of MTRX1011A....

2008-07-24 12:01:22

ImmunoCellular Therapeutics, a biotechnology company, has signed a research agreement with UK-based biotechnology company Antitope for the humanization of IMUC's monoclonal antibodies. ImmunoCellular Therapeutics (IMUC) is advancing its monoclonal antibodies toward clinical trials, and humanizing the antibodies will provide for a safer therapeutic with less immunogenicity potential. IMUC, through its recent acquisition of monoclonal antibody-related technology from Molecular Discoveries,...

2008-07-17 09:01:20

ROCKVILLE, Md., July 17 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the acquisition of Raven Biotechnologies, Inc., a privately held biotechnology company in South San Francisco, California, focused on the discovery and development of monoclonal antibody therapeutics for oncology through its cancer stem cell program. Raven has developed a portfolio...

2008-07-15 09:01:35

Medical Research Council Technology and Biolex Therapeutics have announced that MRCT has successfully completed the humanization of a novel antibody targeting CD20, indicated in non-Hodgkin's lymphoma and rheumatoid arthritis. Biolex is applying its proprietary glycosylation optimization technology to the antibody, BLX-301, to enhance efficacy and potency of the product candidate and potentially reduce certain side effects. Biolex will retain all development and commercialization rights...

2008-07-15 09:01:35

BERKELEY, Calif., July 15, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, today announced that results from two ongoing Phase 1 studies of XOMA 052 in Type 2 diabetes will be presented at the 44th European Association for the Study of Diabetes (EASD) Annual Meeting that will be held in Rome, Italy on September 7-11, 2008. The oral presentation, titled "XOMA 052, an Anti-IL-1beta Antibody, in a Double-Blind,...

2008-07-14 09:01:11

MRC Technology (MRCT) (London, UK) and Biolex Therapeutics, Inc. (Pittsboro, North Carolina, USA) announced today that MRCT had successfully completed the humanization of a novel antibody targeting CD20, indicated in non-Hodgkin's lymphoma and rheumatoid arthritis. Biolex is applying its proprietary glycosylation optimization technology to the antibody, BLX-301, to enhance efficacy and potency of the product candidate and potentially reduce certain side effects. "We are delighted to have...

2008-06-24 06:01:08

NEW YORK, June 24 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (BULLETIN BOARD: ILNS) and MRC Technology (MRCT) announced today they have achieved an important milestone through their collaborative efforts to humanize Intellect's lead antibody IN-N01 necessary for creating a therapeutic antibody for the treatment of Alzheimer's disease. The antibody is intended to be used to promote clearance from the brain of beta amyloid, the toxin that leads to Alzheimer's disease. IN-N01...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related